XML 31 R20.htm IDEA: XBRL DOCUMENT
v3.26.1

EQUITY-BASED COMPENSATION | 6 Months Ended
--- | ---
Mar. 31, 2026
Share-Based Payment Arrangement [Abstract] |
EQUITY-BASED COMPENSATION | EQUITY-BASED COMPENSATION A summary of equity-based compensation expense for continuing operations recognized during the three and six months ended March 31, 2026 and 2025 is as follows:
| Three Months Ended March 31, |  | Six Months Ended March 31, |  |
| 2026 |  | 2025 |  | 2026 |  | 2025 |  |
Stock options | $ | 1,855 |  |  | $ | 1,502 |  |  | $ | 3,201 |  |  | $ | 3,825 |  |  |
Restricted stock units | 2,764 |  |  | 2,043 |  |  | 6,596 |  |  | 3,326 |  |  |
Equity-based compensation expense | $ | 4,619 |  |  | $ | 3,545 |  |  | $ | 9,797 |  |  | $ | 7,151 |  |  |
In connection with the sale of the Healthcare RCM Business, $387 and $595 of the Company's equity-based compensation expense was classified within "net income from discontinued operations" in the accompanying condensed consolidated statements of operations during three and six months ended March 31, 2025, respectively. Amounts are included in costs of services and in selling, general and administrative expense on the condensed consolidated statements of operations. Current and deferred income tax benefits for continuing operations of $472 and $1,202 were recognized during the three and six months ended March 31, 2026, respectively, and current and deferred income tax expense of $1,165 and $588 during the three and six months ended March 31, 2025, respectively. Stock Options In May 2018, the Company adopted the 2018 Equity Incentive Plan (the “2018 Plan”) under which the Company may grant up to 3,500,000 stock options and other equity-based awards to employees, directors and officers. The number of shares of Class A common stock available for issuance under the 2018 Plan includes an annual increase on the first day of each calendar year equal to 4.0% of the outstanding shares of all classes of the Company's common stock as of the last day of the immediately preceding calendar year, unless the Company’s board of directors determines prior to the last trading day of December of the immediately preceding calendar year that the increase shall be less than 4.0%. As of March 31, 2026, equity awards with respect to 2,303,073 shares of the Company's Class A common stock were available for grant under the 2018 Plan. In September 2020, the Company adopted the 2020 Acquisition Equity Incentive Plan (the “2020 Inducement Plan”) under which the Company may grant up to 1,500,000 stock options and other equity-based awards to individuals that were not previously employees of the Company or its subsidiaries in connection with acquisitions, as a material inducement to the individual's entry into employment with the Company or its subsidiaries within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. In May 2021, the Company amended the 2020 Inducement Plan to increase the number of shares of the Company's Class A common stock available for issuance from 1,500,000 to 3,000,000 shares. As of March 31, 2026, equity awards with respect to 2,021,344 shares of the Company's Class A common stock were available for grant under the 2020 Inducement Plan. Share-based compensation expense includes the estimated effects of forfeitures, which will be adjusted over the requisite service period to the extent actual forfeitures differ or are expected to differ from such estimates. A summary of stock option activity for the six months ended March 31, 2026 is as follows:
| Stock Options |  | Weighted Average Exercise Price
Outstanding at September 30, 2025 | 7,881,236 |  |  | $ | 24.61 |
Granted | 1,245,000 |  |  | 23.61 |
Exercised | (181,032) |  |  | 23.42 |
Forfeited and cancelled | (94,632) |  |  | 26.60 |
Outstanding at March 31, 2026 | 8,850,572 |  |  | $ | 24.48 |
Exercisable at March 31, 2026 | 6,800,178 |  |  | $ | 24.95 |
The weighted-average grant date fair value of stock options granted during the six months ended March 31, 2026 was $12.41. As of March 31, 2026, there were 8,850,572 stock options outstanding, of which 6,800,178 were exercisable. As of March 31, 2026, total unrecognized compensation expense related to unvested stock options, including an estimate for pre-vesting forfeitures, was $19,895, which is expected to be recognized over a weighted-average period of 3.5 years. The total fair value of stock options that vested during the three and six months ended March 31, 2026 was $4,163 and $4,837, respectively. Restricted Stock Units The Company has issued Class A common stock in the form of restricted stock units ("RSUs") under the 2018 Plan. A summary of activity related to restricted stock units for the six months ended March 31, 2026 is as follows:
| Restricted Stock Units |  | Weighted Average Grant Date Fair Value
Outstanding at September 30, 2025 | 1,160,641 |  |  | $ | 24.89 |
Granted | 401,826 |  |  | 24.06 |
Vested | (391,916) |  |  | 24.73 |
Forfeited and cancelled | (34,547) |  |  | 23.64 |
Outstanding at March 31, 2026 | 1,136,004 |  |  | $ | 24.69 |
The weighted-average grant date fair value of RSUs granted during three and six months ended March 31, 2026 was $24.06. As of March 31, 2026, total unrecognized compensation expense related to unvested RSUs, including an estimate for pre-vesting forfeitures, was $21,096, which is expected to be recognized over a weighted average period of 2.6 years. The total fair value of RSUs that vested during the three and six months ended March 31, 2026 was $5,449 and $9,693, respectively.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration